Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 4/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.39 |
| ▸ | ACP1 | P24666 | 1/20 | 0.35 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.35 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.35 |
| ▸ | SSU72 | Q9NP77 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13090610 | 0.93 | TGM2 (0.42) | APPADRB2 | |
| SCHEMBL14752729 | 0.89 | BCHE (0.40) | ADRB2MEN1KMT2A | |
| SCHEMBL3978396 | 0.86 | ADRB2 (0.43) | ADRB2MEN1KMT2AADRB1ADRB3 | |
| SCHEMBL967765 | 0.84 | ADRB2 (0.45) | ADRB2ADRB1ADRB3 | |
| SCHEMBL967764 | 0.84 | ADRB2 (0.45) | ADRB2ADRB1ADRB3 | |
| SCHEMBL967763 | 0.84 | ADRB2 (0.45) | ADRB2ADRB1ADRB3 | |
| SCHEMBL5279069 | 0.83 | ADRB2 (0.38) | ADRB2ADRB1ADRB3 | |
| SCHEMBL965283 | 0.82 | ADRB2 (0.49) | ADRB2 | |
| SCHEMBL965287 | 0.82 | ADRB2 (0.49) | ADRB2 | |
| SCHEMBL965285 | 0.82 | ADRB2 (0.49) | ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130060034-A1 | ALIPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS WITH BETA AGONIST ACTIVITY | JOHNSON MICHAEL ROSS (US) | 2013-03-07 | — | — | US | disclosed |
| US-8324218-B2 | Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity | PARION SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100267746-A1 | ALIPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS WITH BETA AGONIST ACTIVITY | PARION SCIENCES, INC. (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267746-A1 | ALIPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS WITH BETA AGONIST ACTIVITY | ADRB1, ADRB2, ADRA2B | APP 667/4885ADRB2 2/4885ACP1 4742/4885 |
| US-20130060034-A1 | ALIPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS WITH BETA AGONIST ACTIVITY | SCNN1G, SCNN1B, TRPV1 | APP 1232/4885ADRB2 21/4885ACP1 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.